The Journal of clinical endocrinology and metabolism · 2011
Treatment of pediatric Graves' disease is associated with excessive weight gain.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Veenendaal Nicole R, Rivkees Scott A
Аннотация
CONTEXT: Little information is available about changes in body weight and body mass index in children before, during, and after treatment for Graves' disease (GD).
OBJECTIVE: Our objective was to examine changes in body weight after treatment for GD in children as related to clinical features.
DESIGN: The medical records of 43 pediatric patients with GD [35 girls and eight boys, aged 4.0-18.5 (mean 10.9) yr] were examined. Patients were included if clinical data were available for 1 yr before and after the diagnosis of GD.
MAIN OUTCOME MEASURES: Weight, height, body mass index (BMI) z-scores, and thyroid hormone levels were assessed.
RESULTS: Overall, patients presented with an average BMI z-score of -0.02 ± 1.05 that was not different from the normal population (P = 0.921) or their premorbid values (P = 0.07). However, in the subset of patients who were initially overweight or obese in the premorbid state, the BMI decreased significantly during the development of hyperthyroidism (P < 0.05). After initiation of treatment, patients gained significant amounts of weight over the first 6 months leading to elevated BMI z-scores (P < 0.0001), and elevations in BMI persisted in about 25% of the patients.
CONCLUSION: Excessive weight gain within 6 months of treatment is seen in children treated for GD, and the gain in weight can persist.
OBJECTIVE: Our objective was to examine changes in body weight after treatment for GD in children as related to clinical features.
DESIGN: The medical records of 43 pediatric patients with GD [35 girls and eight boys, aged 4.0-18.5 (mean 10.9) yr] were examined. Patients were included if clinical data were available for 1 yr before and after the diagnosis of GD.
MAIN OUTCOME MEASURES: Weight, height, body mass index (BMI) z-scores, and thyroid hormone levels were assessed.
RESULTS: Overall, patients presented with an average BMI z-score of -0.02 ± 1.05 that was not different from the normal population (P = 0.921) or their premorbid values (P = 0.07). However, in the subset of patients who were initially overweight or obese in the premorbid state, the BMI decreased significantly during the development of hyperthyroidism (P < 0.05). After initiation of treatment, patients gained significant amounts of weight over the first 6 months leading to elevated BMI z-scores (P < 0.0001), and elevations in BMI persisted in about 25% of the patients.
CONCLUSION: Excessive weight gain within 6 months of treatment is seen in children treated for GD, and the gain in weight can persist.